Evidence map›Paper›PMID 12163591›Full record

ArticleJournal of virology2002

Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF.

Shih-Min Huang, D J McCance

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 176 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Epigenetic approaches for cervical neoplasia screening (Review).Experimental and therapeutic medicine · 2021
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Role of Virus-Induced Host Cell Epigenetic Changes in Cancer.International journal of molecular sciences · 2021
    Review
  19. Review
  20. Review

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Shih-Min HuangDepartment of Microbiology and Immunology. The Cancer Center, University of Rochester, Rochester, New York 14642, USA.
D J McCance
University of Rochester · US

Funding

CO-ACTIVATOR FUNCTION IN ORAL CANCER CELLSR01DE013526 · NIDCR · UNIVERSITY OF ROCHESTER · PI MCCANCE, DENNIS J. · 2000 to 2004
$1.4M
Nanocarriers for Vaccine DeliveryR56AI099008 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI CLEMENTS, JOHN D · 2013 to 2013
$566k
NIAID NIH HHS P01 AI-99-008NIDCR NIH HHS DE13526NIDCR NIH HHS R01 DE013526
6 · The paper itself

Abstract

Previously, we reported that human papillomavirus (HPV) type 16 E6 binds to C/H1, C/H3, and the C-terminal domains of coactivators p300 and CBP, causing the modulation of the transcription of certain genes controlled by NF-kappaB (p65 or relA) and p53. To establish the biological significance of these observations, we have focused on the transcriptional regulation of interleukin-8 (IL-8), a potent chemoattractant for T lymphocytes and neutrophils, which is also essential for the initiation of the local immune response. The IL-8 promoter is regulated by NF-kappaB/p65 in response to tumor necrosis factor alpha and requires the cooperation of the coactivators CBP/p300 and steroid receptor coactivator 1 (SRC-1) and the p300/CBP-associated factor (P/CAF) for optimal activation. Here we report that, in the presence of HPV-16 E6, the promoter activity of IL-8 was repressed. Moreover, from the mutational analysis of the IL-8 promoter, we found that E6 down-regulates the IL-8 promoter activity through the NF-kappaB/p65 binding site. This inhibition appears to result from the ability of HPV-16 E6 to compete with NF-kappaB/p65 and SRC-1 for binding to the N terminus and C terminus of CBP, respectively. Reporter data also showed that E7 represses IL-8 promoter activity, though to a lesser extent than E6 but, like E6, the repression by E7 is through the NF-kappaB/p65 binding site. E7 was shown for the first time to bind to P/CAF, and the binding was necessary for the down regulation of the IL-8 promoter. E6 and E7 together inhibited transcription of the IL-8 promoter to a greater extent than either alone. Finally, by RNase protection assay, we showed that the synthesis of endogenous IL-8 mRNA was repressed in keratinocytes stably expressing E6 and E7. Taken together, the results provide evidence that E6 and E7 can cooperatively disrupt IL-8 transcription through disruption of transcriptional active complexes, and this may have important consequences for immune responses in infected hosts.

Indexed as

Down-RegulationRepressor ProteinsAcetyltransferasesBinding, CompetitiveBinding SitesCell Cycle ProteinsCells, CulturedHistone AcetyltransferasesHumansInterleukin-8KeratinocytesMutationNF-kappa BNuclear ProteinsNuclear Receptor Coactivator 1Oncogene Proteins, ViralAcetyltransferasesCell Cycle ProteinsE6 protein, Human papillomavirus type 16Histone AcetyltransferasesInterleukin-8NCOA1 protein, humanNF-kappa BNuclear ProteinsNuclear Receptor Coactivator 1oncogene protein E7, Human papillomavirus type 16Oncogene Proteins, Viralp300-CBP-Associated Factorp300-CBP Transcription FactorsPapillomavirus E7 ProteinsRepressor ProteinsTrans-ActivatorsTranscription Factors

Identifiers

PMID12163591
PMCPMC136974
OpenAlexW2000704250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.